AZN Astrazeneca Plc

By Ian Walker

AstraZeneca PLC said Tuesday that the European Commission has conditionally approved Koselugo in the European Union for children with neurofibromatosis type 1 and plexiform neurofibromas.

The pharmaceutical giant said that Koselugo reduced tumor volume, pain and improved life quality in a Sprint Phase 2 trial.

Neurofibromatosis type 1 is a rare and debilitating genetic condition affecting one in 3,000 individuals world-wide.

Koselugo is already approved in the U.S. and several other countries for the treatment of pediatric patients with NF1 and symptomatic, inoperable plexiform neurofibromas.

Write to Ian Walker at ian.walker@wsj.com

(END) Dow Jones Newswires

June 22, 2021 02:29 ET (06:29 GMT)

Copyright (c) 2021 Dow Jones & Company, Inc.